Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1001020160140010010
Journal of Urologic Oncology
2016 Volume.14 No. 1 p.10 ~ p.17
Quality of Life in Prostate Cancer Patient Undergoing Androgen Deprivation Therapy
½Åº¸¼º:Shin Bo-Sung
°­Åÿø:Kang Taek-Won
Abstract
Androgen deprivation therapy(ADT) has been one of the standard protocol for treating prostate cancer. The role for hormonal treatment initially was restricted to men with metastatic and inoperable, locally advanced disease. Now it has been extended to neoadjuvant or adjuvant therapy for surgery and radiotherapy, for biochemical relapse after surgery or radiation, and even as primary therapy for non-metastatic disease. Although ADT can improve survival, it can also cause significant morbidity and a decrement in quality of life(QOL). In this article, we discuss QOL problem caused by ADT and suggest for mitigating harm of ADT.
KEYWORD
Prostate Neoplasms, Gonadotropin-releasing hormone, Quality of life
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)